{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T04:01:28Z","timestamp":1791000088597,"version":"4.1.0"},"reference-count":57,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2010,12,17]],"date-time":"2010-12-17T00:00:00Z","timestamp":1292544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>CMX001 (phosphonic acid, [[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]mono[3-(hexadecyloxy)propyl] ester) is a lipid conjugate of the acyclic nucleotide phosphonate, cidofovir (CDV). CMX001 is currently in Phase II clinical trials for the prophylaxis of human cytomegalovirus infection and under development using the Animal Rule for smallpox infection. It has proven effective in reduction of morbidity and mortality in animal models of human smallpox, even after the onset of lesions and other clinical signs of disease. CMX001 and CDV are active against all five families of double-stranded DNA (dsDNA) viruses that cause human morbidity and mortality, including orthopoxviruses such as variola virus, the cause of human smallpox. However, the clinical utility of CDV is limited by the requirement for intravenous dosing and a high incidence of acute kidney toxicity. The risk of nephrotoxicity necessitates pre-hydration and probenecid administration in a health care facility, further complicating high volume CDV use in an emergency situation. Compared with CDV, CMX001 has a number of advantages for treatment of smallpox in an emergency including greater potency in vitro against all dsDNA viruses that cause human disease, a high genetic barrier to resistance, convenient oral administration as a tablet or liquid, and no evidence to date of nephrotoxicity in either animals or humans. The apparent lack of nephrotoxicity observed with CMX001 in vivo is because it is not a substrate for the human organic anion transporters that actively secrete CDV into kidney cells. The ability to test the safety and efficacy of CMX001 in patients with life-threatening dsDNA virus infections which share many basic traits with variola is a major advantage in the development of this antiviral for a smallpox indication.<\/jats:p>","DOI":"10.3390\/v2122740","type":"journal-article","created":{"date-parts":[[2010,12,17]],"date-time":"2010-12-17T11:57:53Z","timestamp":1292587073000},"page":"2740-2762","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":161,"title":["Development of CMX001 for the Treatment of Poxvirus Infections"],"prefix":"10.3390","volume":"2","author":[{"given":"Randall","family":"Lanier","sequence":"first","affiliation":[{"name":"Chimerix, Inc., 2505 Meridian Parkway, Suite 340, Durham, North Carolina, NC 27713, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Trost","sequence":"additional","affiliation":[{"name":"Chimerix, Inc., 2505 Meridian Parkway, Suite 340, Durham, North Carolina, NC 27713, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Tippin","sequence":"additional","affiliation":[{"name":"Chimerix, Inc., 2505 Meridian Parkway, Suite 340, Durham, North Carolina, NC 27713, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Lampert","sequence":"additional","affiliation":[{"name":"Chimerix, Inc., 2505 Meridian Parkway, Suite 340, Durham, North Carolina, NC 27713, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Robertson","sequence":"additional","affiliation":[{"name":"Chimerix, Inc., 2505 Meridian Parkway, Suite 340, Durham, North Carolina, NC 27713, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Foster","sequence":"additional","affiliation":[{"name":"Chimerix, Inc., 2505 Meridian Parkway, Suite 340, Durham, North Carolina, NC 27713, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Rose","sequence":"additional","affiliation":[{"name":"Chimerix, Inc., 2505 Meridian Parkway, Suite 340, Durham, North Carolina, NC 27713, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Painter","sequence":"additional","affiliation":[{"name":"Chimerix, Inc., 2505 Meridian Parkway, Suite 340, Durham, North Carolina, NC 27713, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"O\u2019Mahony","sequence":"additional","affiliation":[{"name":"Chimerix, Inc., 2505 Meridian Parkway, Suite 340, Durham, North Carolina, NC 27713, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrick","family":"Almond","sequence":"additional","affiliation":[{"name":"Chimerix, Inc., 2505 Meridian Parkway, Suite 340, Durham, North Carolina, NC 27713, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Painter","sequence":"additional","affiliation":[{"name":"Chimerix, Inc., 2505 Meridian Parkway, Suite 340, Durham, North Carolina, NC 27713, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2010,12,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1056\/NEJMra020025","article-title":"Diagnosis and management of smallpox","volume":"346","author":"Breman","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_2","unstructured":"Fenner, F., Henderson, D.A., Arita, I., Jezek, Z., and Ladnyi, I.D. (1988). Smallpox and its Eradication, World Health Organization."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.3201\/eid0911.030369","article-title":"Risks and benefits of preexposure and postexposure smallpox vaccination","volume":"9","author":"Meltzer","year":"2003","journal-title":"Emerg. Infect. Dis."},{"key":"ref_4","unstructured":"Tucker, J. (2006). Scourge: The Once and Future Threat of Smallpox, Altantic Monthly Press."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Chen, N., Bellone, C.J., Schriewer, J., Owens, G., Frederickson, T., Parker, S., and Buller, R.M.L. (2010). Poxvirus interleukin-4 expression overcomes inherent resistance and vaccine-induced immunity: Pathogenesis, prophylaxis and antiviral therapy. Virology, Available online: http:\/\/www.sciencedirect.com\/science\/journal\/00426822.","DOI":"10.1016\/j.virol.2010.10.021"},{"key":"ref_6","unstructured":"Hardman, J.G., Limbird, L.E., Molinoff, P.B., Ruddon, R.W., and Gilman, A.G. (1996). Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics, McGraw-Hill."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1369-5274(98)80086-6","article-title":"New antivirals\u2014Mechanism of action and resistance development","volume":"1","author":"Balzarini","year":"1998","journal-title":"Curr. Opin. Microbiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.tibtech.2004.06.008","article-title":"Design and development of oral drugs for the prophylaxis and treatment of smallpox infection","volume":"22","author":"Painter","year":"2004","journal-title":"Trends Biotechnol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/0006-2952(93)90670-R","article-title":"Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells","volume":"46","author":"Connelly","year":"1993","journal-title":"Biochem. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0026-895X(25)09608-7","article-title":"Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells","volume":"50","author":"Cihlar","year":"1996","journal-title":"Mol. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/375743","article-title":"Viral DNA polymerase mutations associated with drug resistance in human cytomegalovirus","volume":"188","author":"Chou","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0166-3542(02)00098-0","article-title":"Sequence changes in the human adenovirus type 5 DNA polymerase associated with resistance to the broad spectrum antiviral cidofovir","volume":"56","author":"Kinchington","year":"2002","journal-title":"Antivir. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1128\/AAC.01172-07","article-title":"Cidofovir and (S)-9-[3-hydroxy-(2-phosphonomethoxy)propyl]adenine are highly effective inhibitors of vaccinia virus DNA polymerase when incorporated into the template strand","volume":"52","author":"Magee","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1128\/AAC.41.3.594","article-title":"Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation","volume":"41","author":"Xiong","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_15","unstructured":"(2009, January 22). Poxvirus Bioinformatics Resource Center. Available online: http:\/\/www.poxvirus.org."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1093\/nar\/25.17.3389","article-title":"Gapped BLAST and PSI-BLAST: A new generation of protein database search programs","volume":"25","author":"Altschul","year":"1997","journal-title":"Nucleic. Acids Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1086\/426831","article-title":"Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: Activity against adenovirus replication in vitro","volume":"191","author":"Hartline","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1128\/AAC.49.9.3724-3733.2005","article-title":"Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro","volume":"49","author":"Hartline","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_19","unstructured":"Christensen, N. (2007). Penn State College of Medicine, Hershey, PA, USA, Study report."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1128\/AAC.50.4.1564-1566.2006","article-title":"Ether lipid ester derivatives of cidofovir inhibit polyomavirus BK replication in vitro","volume":"50","author":"Randhawa","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4723","DOI":"10.1128\/AAC.00837-10","article-title":"Hexadecyloxypropyl-cidofovir, CMX001, suppresses JC virus replication in human fetal brain SVG cell cultures","volume":"54","author":"Jiang","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","first-page":"A66","article-title":"Orally active ether lipid prodrugs of cidofovir for the treatment of smallpox","volume":"53","author":"Huggins","year":"2002","journal-title":"Antivir. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1128\/AAC.46.4.991-995.2002","article-title":"Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir","volume":"46","author":"Kern","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.virol.2003.11.015","article-title":"Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model","volume":"318","author":"Buller","year":"2004","journal-title":"Virology"},{"key":"ref_25","unstructured":"Prichard, M.N. Personal communication by email."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1128\/AAC.46.5.1329-1335.2002","article-title":"Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses","volume":"46","author":"Smee","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"4038","DOI":"10.1128\/AAC.00380-06","article-title":"Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype","volume":"50","author":"Kornbluth","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"9391","DOI":"10.1128\/JVI.00605-06","article-title":"Cidofovir resistance in vaccinia virus is linked to diminished virulence in mice","volume":"80","author":"Andrei","year":"2006","journal-title":"J. Virol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1743-422X-5-58","article-title":"Isolation and characterization of cidofovir resistant vaccinia viruses","volume":"5","author":"Becker","year":"2008","journal-title":"Virol. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"12520","DOI":"10.1128\/JVI.01528-08","article-title":"Mechanism of antiviral drug resistance of vaccinia virus: Identification of residues in the viral DNA polymerase conferring differential resistance to antipoxvirus drugs","volume":"82","author":"Gammon","year":"2008","journal-title":"J. Virol."},{"key":"ref_31","unstructured":"(2002). Approval of New Drugs When Human Efficacy Studies Are Not Ethical or Feasible, Code of Federal Regulations, Part 314, Subpart I, Title 21."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1358\/dof.2008.033.08.1233987","article-title":"CMX001. Anti-smallpox agent, anti-cytomegalovirus agent, viral polymerase inhibitor","volume":"33","author":"Painter","year":"2010","journal-title":"Drugs Future"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jama.1997.03550050061035","article-title":"Clinical recognition and management of patients exposed to biological warfare agents","volume":"278","author":"Franz","year":"1997","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.3390\/v2091918","article-title":"Ectromelia virus infections of mice as a model to support the licensure of anti-orthopoxvirus therapeutics","volume":"2","author":"Parker","year":"2010","journal-title":"Viruses"},{"key":"ref_35","unstructured":"Buller, R.M.L. (2009). Saint Louis University, Saint Louis, MO, USA, Study report."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.antiviral.2007.08.003","article-title":"Efficacy of therapeutic intervention with an oral ether-lipid analogue of cidofovir (CMX001) in a lethal mousepox model","volume":"77","author":"Parker","year":"2008","journal-title":"Antivir. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1128\/AAC.48.2.404-412.2004","article-title":"Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir","volume":"48","author":"Quenelle","year":"2004","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"11084","DOI":"10.1128\/JVI.00423-07","article-title":"Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox","volume":"81","author":"Adams","year":"2007","journal-title":"J. Virol."},{"key":"ref_39","first-page":"453","article-title":"Experimental respiratory infection with poxviruses. I. Clinical virological and epidemiological studies","volume":"47","author":"Westwood","year":"1966","journal-title":"Br. J. Exp. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Rice, A.D., Adams, M.M., Wallace, G., Burrage, A.M., Lindsey, S.F., Smith, A.J., Swetnam, D., Manning, B.R., Gray, S.A., Lampert, B., Foster, S., Lanier, R., Robertson, A., Painter, G., and Moyer, R.W. (Viruses, 2010). Efficacy of CMX001 as a post exposure antiviral in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans, Viruses, (submitted for publication).","DOI":"10.3390\/v3010047"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Rice, A.D., Adams, M.M., Lampert, B., Foster, S., Lanier, R., Robertson, A., Painter, G.R., and Moyer, R.W. (Viruses, 2010). Efficacy of CMX001 as a Prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans, Viruses, (submitted for publication).","DOI":"10.3390\/v3020063"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature02331","article-title":"Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox","volume":"428","author":"Earl","year":"2004","journal-title":"Nature"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4433","DOI":"10.1128\/JVI.78.9.4433-4443.2004","article-title":"Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox","volume":"78","author":"Hooper","year":"2004","journal-title":"J. Virol."},{"key":"ref_44","first-page":"A57","article-title":"Successful cidofovir treatment of smallpox-like disease in Variola and monkeypox primate models","volume":"62","author":"Huggins","year":"2004","journal-title":"Antivir. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.vaccine.2007.10.063","article-title":"Clonal vaccinia virus grown in cell culture fully protects monkeys from lethal monkeypox challenge","volume":"26","author":"Marriott","year":"2008","journal-title":"Vaccine"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0272-2712(18)30018-0","article-title":"Clinical recognition and management of patients exposed to biological warfare agents","volume":"21","author":"Franz","year":"2001","journal-title":"Clin. Lab. Med."},{"key":"ref_47","unstructured":"Lampert, B.M., Almond, M.A., and Trost, L.C. (2008, January 16\u201320). Species-dependent pharmacokinetics of CMX001, an orally-available prodrug of cidofovir being developed for treatment of poxvirus infection. In Proceeding of the 47th SOT Annual Meeting, Seattle, WA, USA."},{"key":"ref_48","unstructured":"Trost, L.C., Tippin, T.K., Anderson, M.A., and Painter, W.P. (2010, January 12\u201315). Compromised renal function does not affect the pharmacokinetics of CMX001 in patients with severe double-stranded DNA virus infections. In Proceeding of the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, USA."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-3565(24)36999-X","article-title":"The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data","volume":"283","author":"Obach","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_50","first-page":"149","article-title":"In vitro hepatic metabolism of CMX001, a lipid conjugate of cidofovir","volume":"41","author":"Tippin","year":"2009","journal-title":"Drug Metab. Rev."},{"key":"ref_51","unstructured":"Tippin, T.K., Lampert, B.M., Robertson, A., Anderson, M., Almond, M.R., Painter, G.R., and Trost, L.C. (Antimicrob. Agents Chemother., 2010). Differences in monkey and human pharmacokinetics and metabolism of CMX001, a lipid conjugate of cidofovir, Antimicrob. Agents Chemother., to be submitted for publication."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1681\/ASN.V113383","article-title":"Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1","volume":"11","author":"Ho","year":"2000","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_53","unstructured":"Tippin, T.K., Lampert, B.M., Painter, G.P., and Lanier, R. (2010, January 14\u201318). Lipid conjugates of cidofovir and tenofovir, CMX001 and CMX157, are not substrates of human organic anion transporters OAT1 and OAT3. In Proceeding of the American Association of Pharmaceutical Scientists Annual Meeting, New Orleans, LA, USA."},{"key":"ref_54","unstructured":"Tippin, T.K., Lampert, B., Painter, G., and Lanier, R. (J. Pharmacol. Exp. Ther., 2010). CMX001, a lipid conjugate of cidofovir: Lack of human organic anion transporter-mediated uptake in vitro and reduced kidney distribution in mice compared to cidofovir, J. Pharmacol. Exp. Ther., to be submitted for publication."},{"key":"ref_55","unstructured":"Florescu, D.F., Igdon, J., Pergam, S.A., Neely, M., Johnston, C., Way, S.S., Sande, J., Lewinsohn, D., Guzman-Cottrill, J., Kurtzberg, J., Papanicolaou, G., Graham, M.L., Painter, W., Lanier, R., Mommeja-Marin, H., Anderson, M., and van der Horst, C. (2010, January 21\u201324). Experience with CMX001, a novel antiviral drug, for adenovirus infections in immunocompromised patients. In Proceeding of the IDSA 48th Annual Meeting, Vancouver, BC, Canada."},{"key":"ref_56","unstructured":"Centers for Disease Control and Prevention (2009). Progressive vaccinia in a military smallpox vaccinee\u2015United States, 2009. MMWR Morb. Mortal. Wkly. Rep., 58, 532\u2013536."},{"key":"ref_57","first-page":"211 (Abstract# LB10)","article-title":"First use of CMX001, a novel antiviral drug, for the suppression of cytomegalovirus infection in solid organ transplant patients: A case series","volume":"10","author":"Painter","year":"2010","journal-title":"Am. J. Transplant."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/2\/12\/2740\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T22:04:08Z","timestamp":1760220248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/2\/12\/2740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,17]]},"references-count":57,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2010,12]]}},"alternative-id":["v2122740"],"URL":"https:\/\/doi.org\/10.3390\/v2122740","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,17]]}}}